Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment
Introduction A case of multiple liver metastases of clear cell RCC with a significant response to sunitinib as the fifth line after nivolumab is reported. Case presentation The patient was a 65‐year‐old man who underwent open nephrectomy for RCC. After the nephrectomy, he had recurrences several tim...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12545 |
| _version_ | 1797966550294069248 |
|---|---|
| author | Kouki Tada Kei Daizumoto Masayuki Takahashi Hisanori Uehara Megumi Tsuda Yoshito Kusuhara Tomoya Fukawa Yasuyo Yamamoto Kunihisa Yamaguchi Hiro‐omi Kanayama |
| author_facet | Kouki Tada Kei Daizumoto Masayuki Takahashi Hisanori Uehara Megumi Tsuda Yoshito Kusuhara Tomoya Fukawa Yasuyo Yamamoto Kunihisa Yamaguchi Hiro‐omi Kanayama |
| author_sort | Kouki Tada |
| collection | DOAJ |
| description | Introduction A case of multiple liver metastases of clear cell RCC with a significant response to sunitinib as the fifth line after nivolumab is reported. Case presentation The patient was a 65‐year‐old man who underwent open nephrectomy for RCC. After the nephrectomy, he had recurrences several times, and metastasectomy had been performed for each recurrence. At 13 years after the nephrectomy, multiple liver, and lung metastases appeared. The treatment was switched to axitinib, followed by cabozantinib, then nivolumab. The best response was PR, SD, and PD for these three drugs, and treatment duration was 14, 3, and 3 months, respectively. As the fifth line, sunitinib was administered, with significant shrinkage of the multiple liver metastases, and PR has been maintained for 34 months. Conclusion Sunitinib after an IO‐drug showed a significant effect in spite of only slight efficacy with other VEGFR‐TKIs, which may have occurred through the alteration of the immunological microenvironment. |
| first_indexed | 2024-04-11T02:17:13Z |
| format | Article |
| id | doaj.art-76c44c33980943568e382af2e4341b43 |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-04-11T02:17:13Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-76c44c33980943568e382af2e4341b432023-01-03T00:53:56ZengWileyIJU Case Reports2577-171X2023-01-0161414410.1002/iju5.12545Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatmentKouki Tada0Kei Daizumoto1Masayuki Takahashi2Hisanori Uehara3Megumi Tsuda4Yoshito Kusuhara5Tomoya Fukawa6Yasuyo Yamamoto7Kunihisa Yamaguchi8Hiro‐omi Kanayama9Department of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima JapanDepartment of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima JapanDepartment of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima JapanDivision of Pathology Tokushima University Hospital Tokushima JapanDepartment of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima JapanDepartment of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima JapanDepartment of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima JapanDepartment of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima JapanDepartment of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima JapanDepartment of Urology Tokushima University Graduate School of Biomedical Sciences Tokushima JapanIntroduction A case of multiple liver metastases of clear cell RCC with a significant response to sunitinib as the fifth line after nivolumab is reported. Case presentation The patient was a 65‐year‐old man who underwent open nephrectomy for RCC. After the nephrectomy, he had recurrences several times, and metastasectomy had been performed for each recurrence. At 13 years after the nephrectomy, multiple liver, and lung metastases appeared. The treatment was switched to axitinib, followed by cabozantinib, then nivolumab. The best response was PR, SD, and PD for these three drugs, and treatment duration was 14, 3, and 3 months, respectively. As the fifth line, sunitinib was administered, with significant shrinkage of the multiple liver metastases, and PR has been maintained for 34 months. Conclusion Sunitinib after an IO‐drug showed a significant effect in spite of only slight efficacy with other VEGFR‐TKIs, which may have occurred through the alteration of the immunological microenvironment.https://doi.org/10.1002/iju5.12545molecular‐targeted therapynivolumabrenal cell carcinomasunitinib |
| spellingShingle | Kouki Tada Kei Daizumoto Masayuki Takahashi Hisanori Uehara Megumi Tsuda Yoshito Kusuhara Tomoya Fukawa Yasuyo Yamamoto Kunihisa Yamaguchi Hiro‐omi Kanayama Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment IJU Case Reports molecular‐targeted therapy nivolumab renal cell carcinoma sunitinib |
| title | Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment |
| title_full | Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment |
| title_fullStr | Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment |
| title_full_unstemmed | Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment |
| title_short | Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment |
| title_sort | recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment |
| topic | molecular‐targeted therapy nivolumab renal cell carcinoma sunitinib |
| url | https://doi.org/10.1002/iju5.12545 |
| work_keys_str_mv | AT koukitada recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment AT keidaizumoto recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment AT masayukitakahashi recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment AT hisanoriuehara recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment AT megumitsuda recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment AT yoshitokusuhara recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment AT tomoyafukawa recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment AT yasuyoyamamoto recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment AT kunihisayamaguchi recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment AT hiroomikanayama recurrentmultiplelivermetastasesofclearcellrenalcellcarcinomawithasignificantresponsetosunitinibafternivolumabtreatment |